CTRI/2022/07/044136已完成3 期
A Multicenter, Prospective, Randomized, Open Label, Two-Arm, Parallel-Group, Phase III, Active Controlled, Non-inferiority, Comparative Study to Assess Efficacy and Safety of Tofacitinib Ointment 2% w/w to Pimecrolimus Cream 1% w/w in Patients with Mild to Moderate Atopic Dermatitis (AD). - NA
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 184
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects will be eligible for inclusion in this study only if they meet all of the following criteria:
- •1. Male and female patients, age between 12-60 (both inclusive) years;
- •2. Have a clinical diagnosis of atopic dermatitis (AD) (also known as atopic eczema confirmed to be atopic dermatitis according to the criteria of Hanifin and Rajka) (Refer to Appendix-D);
- •3. Patients with mild to moderate AD based on vIGA-AD score of 2 (mild) or 3 (moderate) at Baseline (Refer to Appendix-C) ;
- •4. Have AD involvement = 5% treatable body surface area (BSA) (excluding the scalp) and up to and including 20% of total BSA at Day 1 using Mostellar formulae;
- •5. Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures;
- •In case of patients with age <18 years, legally acceptable representatives (LAR; e.g. parent/guardian/care-taker) must provide consent and Written Assent will be taken from patients if they are able to comprehend the nature of the study.
- •6. For female subjects: evidence of post-menopause, or, for females of child-bearing age, negative serum or urine pregnancy test prior to randomization;
- •7. Females of child-bearing age (which includes all female subjects aged 12 years and older, regardless of whether they have experienced menarche) must agree to use highly effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with her partner during the study period and for 28 days following their last dose;
- •(Females who are not of childbearing potential are defined as:
- •i. Postmenopausal (defined as at least 12 months with no menses in women =45 years of age); OR
- •ii. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR
- •iii. Have a congenital or acquired condition that prevents childbearing).
排除标准
- •Subjects will not be eligible for inclusion in this study if they meet any of the following criteria:
- •1. Currently experiencing or have a history of other concomitant skin conditions (like, lupus erythematosus, psoriasis or mycosis fungoides that requires frequent hospitalizations and/or continued treatment for skin infections;
- •2. Have clinically unstable AD or having consistent requirement for either oral, or parenteral (including topical) corticosteroids to manage AD signs and symptoms;
- •3. A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past;
- •4. Immunocompromised adults and adolescent, including subjects on systemic immunosuppressive medications;
- •5. Patients with a history of disseminated or recurrent herpes zoster infection;
- •6. Currently experiencing a skin infection or any other infection that requires treatment, or is currently being treated, with topical or systemic antibiotics;
- •7. Any clinically significant medical disorder, condition, or disease or clinically significant physical examination finding at screening visit that may interfere with study objectives/safety of the subjects;
- •8. Patients with history of Tuberculosis (TB) or living with contacts having TB in last 1 year;
- •9. Patients with history of lymphoproliferative disorders or malignancies (except adequately treated or excised nonmetastatic basal cell or squamous cell skin cancer or cervical carcinoma in situ);
- •10. Patients already treated with phototherapy, systemic immunosuppresants, cytostatic drugs, systemic corticosteroid, oral Janus kinase (JAK) inhibitor, Monoclonal antibody, leukotriene antagonist, systemic antibiotics, or herbal medications with unknown properties or known beneficial effects for AD within 1 month prior to randomization;
- •11. Topical therapy (corticosteroids, tars, antihistamines, antibiotic creams, phosphodiesterase 4 [PDE4] inhibitors, retinoids or benzoyl peroxide products [BPO], antibacterial medications or antibacterial products included in soaps, bleach baths, or topical sodium hypochlorite-based products) within 14 days prior to randomization;
- •12. Use of other Investigational products used for the treatment of AD within 2 months prior to randomization;
- •13. Allergic to Tofacitinib or any macrolide or pimecrolimus or any excipients or any component of test/reference formulation;
- •14. Patients with HIV-positive, Hepatitis-B & C-positive;
- •15. Pregnant, lactating women and those planning to get pregnant;
- •16. Patients who participated in other clinical trials within 3 months prior to screening visit or not considered suitable for this trial by the researchers;
- •17. Patients/LAR who did not provide signed informed consent and adolescents who did not provide signed assent.
研究者
相似试验
招募中
3 期
This study is to evaluate benefit of adding Molnupiravir over standard treatments in mild COVID-19 subjectsCTRI/2021/06/033938Dr Reddys Laboratories Limited
招募中
2 期
Effect of Doxycycline and Metformin Gel in PeriodontitisCTRI/2023/03/051072Dr Reddys Laboratories Limited
进行中（未招募）
1 期
Study comparing the action of drugs : ticagrelor, clopidogrel combined with acetylsalicylic acid in preventing ischemic strokes during transcatheter aortic valve implantation operations.Preventing cerebrovascular embolic events during the TAVI procedureMedDRA version: 19.0Level: PTClassification code 10002918Term: Aortic valve stenosisSystem Organ Class: 10007541 - Cardiac disordersEUCTR2015-005630-21-GRational and Kapodistrian University of Athens
进行中（未招募）
不适用
A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing.Epidermolysis bullosaEUCTR2012-001815-21-PTShire Regenerative Medicine, Inc.26
进行中（未招募）
不适用
A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing.Epidermolysis bullosaEUCTR2012-001815-21-ESShire Regenerative Medicine, Inc.25